Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Reports Strong First Quarter 2026 Financial Results and PALSONIFY Adoption
Summary
Crinetics Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, showing a significant increase in net product revenue to $10.3 million, driven by the rapid adoption of PALSONIFY, its first commercial product for acromegaly. The company also provided updates on its clinical trials and regulatory submissions for PALSONIFY and other drug candidates. Despite the increase in revenue, the company reported a net loss of $127.8 million for the quarter. Crinetics continues to expect its 2026 operating expenses to be between $600 million to $650 million.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement